Trajectory-Based Phenotyping After Coronary Artery Bypass Surgery

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBursa Sevket Yilmaz Training and Research Hospital

About this trial

Coronary artery bypass grafting is a commonly performed heart surgery, but patients may have different risks for postoperative complications even when their preoperative risk scores are similar. EuroSCORE II is widely used to estimate surgical risk before cardiac surgery, but it may not fully reflect how the body responds during the early postoperative period.

This retrospective observational study will evaluate adult patients who underwent elective coronary artery bypass grafting with cardiopulmonary bypass between January 1, 2022 and December 31, 2025. The study will use existing hospital records and laboratory data. No additional treatment, test, or intervention will be given to patients as part of this study.

The main aim is to examine whether early postoperative changes in inflammatory and renal laboratory markers can identify different patient subgroups, called phenotypes. These markers include neutrophil-to-lymphocyte ratio, systemic immune-inflammation index, triglyceride-glucose index, and serum creatinine. The study will evaluate whether these phenotype groups are associated with postoperative acute kidney injury and prolonged intensive care unit stay.

The study will also assess whether this early postoperative phenotype-based classification provides additional risk information beyond EuroSCORE II.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adult patients aged 18 years or older

Patients who underwent elective on-pump coronary artery bypass grafting

Patients operated between January 1, 2022 and December 31, 2025

Patients with available perioperative clinical and laboratory data required for analysis

Disqualifiers

Patients undergoing emergency surgery

Patients undergoing concomitant valve surgery

Patients with missing or inconsistent key clinical or laboratory data

Trial population

The study population will consist of adult patients who underwent elective on-pump coronary artery bypass grafting at University of Health Sciences Bursa Yüksek İhtisas Training and Research Hospital between January 1, 2022 and December 31, 2025. Eligible patients will be identified retrospectively from electronic medical records, laboratory databases, and archived patient files.

Trial design

Design model

Cohort

Time perspective

Retrospective

Treatments tested in this trial

  • Early Postoperative Phenotype Classification

    Other intervention

    Patients will be retrospectively classified into phenotype groups based on early postoperative inflammatory and renal biomarker trajectories. This classification is analytical only and does not involve any intervention, treatment assignment, or additional testing.

Treatment groups

1,000 Participants
are divided into 1 treatment group
Group A: Elective CABG Cohort1 intervention

Trial outcomes

Primary outcomes

1

Number of Participants With Prolonged Postoperative Intensive Care Unit Stay

Prolonged postoperative intensive care unit stay was defined as an intensive care unit length of stay exceeding 4 days after elective on-pump coronary artery bypass grafting.

Time frame
From surgery to intensive care unit discharge, assessed up to 30 days after surgery

Secondary outcomes

1

Acute Kidney Injury

Postoperative acute kidney injury defined according to serum creatinine-based KDIGO criteria within the first 72 hours after elective on-pump coronary artery bypass grafting.

Time frame
Within the first 72 hours after surgery
2

In-Hospital Mortality

Death from any cause occurring after elective on-pump coronary artery bypass grafting.

Time frame
From surgery until hospital discharge, assessed up to 30 days after surgery
3

Reintubation

Requirement for endotracheal reintubation after initial postoperative extubation following elective on-pump coronary artery bypass grafting.

Time frame
From surgery until hospital discharge, assessed up to 30 days after surgery
4

Arrhythmia Requiring Treatment

Occurrence of postoperative arrhythmia requiring medical treatment, electrical cardioversion, or another clinically documented therapeutic intervention after elective on-pump coronary artery bypass grafting.

Time frame
From surgery until hospital discharge, assessed up to 30 days after surgery

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: